Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest AcelRx Pharmaceuticals Inc. Stories

2014-04-04 08:25:09

REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9(th). Presentation details are as follows: 13(th) Annual Needham Healthcare Conference Date: Wednesday,...

2014-03-25 08:29:07

REDWOOD CITY, Calif., March 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO). Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial...

2014-03-07 16:23:04

REDWOOD CITY, Calif., March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference: 26(th) Annual Roth ConferenceDate: Tuesday, March 11, 2014Location: The Ritz Carlton, Laguna Niguel, CAPresentation...

2014-03-03 16:25:58

REDWOOD CITY, Calif., March 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. "AcelRx made strong progress in 2013 with the successful completion of the Zalviso(TM) (sufentanil sublingual NanoTab system) Phase 3 program, the...

2014-02-24 08:27:56

REDWOOD CITY, Calif., Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m....

2014-02-05 08:28:52

REDWOOD CITY, Calif., Feb. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows: BIO CEO & Investor ConferenceDate: Tuesday, February...

2013-12-19 08:26:49

REDWOOD CITY, Calif., Dec. 19, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered into a new amended and restated credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) that extends AcelRx's current relationship with Hercules, which was established in June...

2013-12-16 08:25:46

- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - REDWOOD CITY, Calif. and AACHEN, Germany, Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO(TM) (previously known as ARX-01) for potential use in pain treatment within or dispensed by a hospital,...

2013-12-13 08:24:43

- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study...

2013-12-11 08:30:04

REDWOOD CITY, Calif., Dec. 11, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard F. Afable, M.D., president and CEO of Covenant Health Network, was appointed to the company's board of directors. Guy Nohra, co-founder and managing director of venture capital firm Alta Partners,...